Use of faecal markers in screening for colorectal neoplasia: A European group on tumor markers position paper

International Journal of Cancer

Volumn 128, Issue 1, 2011, Pages 3-11

  Duffy, Michael J ^a   Van Rossum, Leo G M ^b   Van Turenhout, Sietze T ^c   Malminiemi, Outi ^d   Sturgeon, Catherine ^e   Lamerz, Rolf ^f   Nicolini, Andrea ^g   Haglund, Caj ^h   Holubec, Lubos ⁱ   Fraser, Callum G ^j   Halloran, Stephen P ^k  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d PIRKANMAA HOSPITAL DISTRICT   (Finland)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY OF PISA   (Italy)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j Scottish Bowel Screening Centre Laboratory   (United Kingdom)

^k ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

more..

Author keywords

Colorectal cancer; EGTM; Faecal occult blood testing; Guidelines; Screening immunochemical test

Indexed keywords

DNA MARKER; GLOBIN; GUAIAC; HEMOGLOBIN; TUMOR MARKER;

ANTIBODY DETECTION; CANCER SCREENING; COLONOSCOPY; COLORECTAL TUMOR; COMPUTED TOMOGRAPHIC COLONOGRAPHY; FALSE NEGATIVE RESULT; FECAL IMMUNOCHEMICAL TEST; GUAIAC FECAL OCCULT BLOOD TEST; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; MASS SCREENING; OCCULT BLOOD; OCCULT BLOOD TEST; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SIGMOIDOSCOPY;

COLORECTAL NEOPLASMS; DNA, NEOPLASM; EUROPE; FECES; HUMANS; MASS SCREENING; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 78349237245     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25654     Document Type: Short Survey

References (80)

1. Parkin DM, Bray F, Pisani P,. Global cancer statistics. CA Cancer J Clin 2005; 55: 74 108.
2. Davies RJ, Miller R, Coleman N,. Colorectal cancer screening: prospects for molecular stools analysis. Nature Rev Cancer 2005; 5: 199 209.
3. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O,. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467 71.
4. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F,. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365 71.
5. Hardcastle JD, Chamberlain JO, Robinson JH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM,. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472 7.
6. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahrén C,. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 1994; 29: 468 73.
7. Lindholm E, Brevinge H, Haglind E,. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95: 1029 36.
8. Advisory Committee on Cancer Prevention. Recommendation on cancer screening in the European union. Eur J Cancer 2000; 36: 1473 8.
9. Council Recommendation of 2 December 2003 on cancer screening. Official J Eur Union 2003, 2003/878/EC: 34 38.
10. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O,. Tumor markers in colorectal cancer: European group on tumor markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348 60.
11. Segnan N, Patnick J, Karsa Lv, editors. European guidelines for quality assurance in colorectal cancer screening and diagnosis, in preparation.
12. NHS Bowel Cancer Screening Programme, Version 3, 31 March 2008. Available at:. Accessed 25 February 2010.
13. Health Council of the Netherlands. A national colorectal cancer screening programme. The Hague: Health Council of the Netherlands, 2009; publication no. 2009/13E. ISBN 978-90-5549-780-5. Available at:. Accessed 25 February 2010.
14. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US multi-society task force on colorectal cancer, and the American college of radiology. CA Cancer J Clin 2008; 58: 130 60.
15. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Colorectal Cancer Screening. Version 1.2010. Available at: Accessed, 25 March 2010.
16. US Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Int Med 2008; 149: 627 37.
17. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C,. Colorectal cancer screening and surveillance: clinical guidelines and rationale, update based on new evidence. Gastroenterology 2003; 124: 544 60.
18. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brnner N, Chan DW, Babaian R, Bast RC, Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54: 11 79.
19. Lieberman DA,. Screening for colorectal cancer. N Engl J Med 2009; 12: 1179 87.
20. Huang CS, Lal SK, Farraye FA,. Colorectal cancer screening in average risk individuals. Cancer Causes Control 2005; 16: 171 88.
21. Kahi CJ, Rex DK, Imperiale TF,. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology 2008; 135: 380 99.
22. Young GP, St John DJ, Winawer SJ, Rozen P,; WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy). Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroenterol 2002; 97: 2499 507.
23. Halloran SP,. Bowel cancer screening. Surgery 2009; 27: 397 400.
24. Allison JE, Tekawa IS, Ransom LJ, Adrain AL,. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155 9.
25. Rabeneck L, Zwaal C, Goodman JH, Mai V, Zamkanei M,. Cancer Care Ontario guaiac fecal occult blood test (FOBT) laboratory standards: evidentiary base and recommendations. Clin Biochem 2008; 41: 1289 305.
26. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E,. Screening for colorectal cancer using fecal the occult blood test, Hemoccult. Cochrane Database of Systematic Reviews 2007, Issue 1, Art. No.: CD001216.
27. Launoy G, Herbert C, Vallee JP, Desoubeaux N, Réaud JM, Ollivier V, Bouvier V, Flachs A, Arsène D, Valla A, Gignoux M,. Mass screening for colorectal cancer in France. Experience in 165,000 people in the department of Calvados. Gastroenterol Clin Biol 1996; 20: 228 36.
28. Zappa M, Castiglione G, Grazzini G, Falini P, Giorgi D, Paci E, Ciatto S,. Effect of faecal occult blood testing on colorectal mortality: results of a population-based case-control study in the district of Florence, Italy. Int J Cancer 1997; 73: 208 10.
29. Bertario L, Russo A, Crosignani P, Sala P, Spinelli P, Pizzetti P, Andreola S, Berrino F,. Reducing colorectal cancer mortality by repeated faecal occult blood test: a nested case-control study. Eur J Cancer 1999; 35: 973 77.
30. Faivre J, Tazi MA, El Mrini T, Lejeune C, Benhamiche AM, Dassonville F,. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. Br J Cancer 1999; 79: 680 3.
31. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, Dassonville F, Bonithon-Kopp C,. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126: 1674 80.
32. UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. Br Med J 2004; 329: 133 35.
33. Malila N, Oivanen T, Malminiemi O, Hakama M,. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ 2008; 20; 337: a2261.
34. Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J,. French colorectal cancer screening pilot programme: results of the first round. J Med Screen 2008; 15: 143 8.
35. Steele RJC, McClements PL, Libby G, Black R, Morton C, Birrell J, Mowat NA, Wilson JA, Kenicer M, Carey FA, Fraser CG,. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009; 58: 530 5.
36. Peris M, Espina JA, Munoz L, Navarro M, Binefa G, Borràs JM,. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen 2007; 14: 81 6.
37. Allison JE,. Colon cancer screening guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology 2005; 129: 745 8.
38. Castiglione G, Zappa M, Grazzini G, Rubeca T, Turco P, Sani C, Ciatto S,. Screening for colorectal cancer by faecal occult blood test: comparison of immunochemical tests. J Med Screen 2000; 7: 35 7.
39. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV,. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462 7.
40. van Rossum LG, van Rijn AF, van Oijen MG, Fockens P, Laheij RJ, Verbeek AL, Jansen JB, Dekker E,. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 2009; 125: 746 50.
41. Brown LF, Fraser CG,. Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. Ann Clin Biochem 2008; 45: 604 5.
42. Grazzini G, Ventura L, Zappa M, Ciatto S, Confortini M, Rapi S, Rubeca T, Visioli CB, Halloran SP,. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut, in press.
43. Young GP, Sinatra MA, St John DJ,. Influence of delay in stool sampling on fecal occult blood sensitivity. Clin Chem 1996; 42: 1107 8.
44. van Rossum LGM, van Rijn AF, Laheij RJF, van Oijen MG, Fockens P, Jansen JB, Verbeek AL, Dekker E,. Cut-off values determines the performance of a semi-quantitative immunochemical fecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009; 101: 1274 81.
45. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y,. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Int Med 2007; 146: 244 55.
46. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, van der Togt AC, Kuipers EJ, Habbema JD, van Leerdam ME,. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009; 101; 1103 10.
47. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, Bortoli A, Castiglione G, Cazzola L, Confortini M, Mantellini P, Rubeca T, Zappa M,. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009; 100: 259 65
48. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, Launoy G,. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 2009; 125: 1127 33.
49. Fraser CG, Matthew CM, Mowat NAG, Wilson JA, Carey FA, Steele RJ,. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol 2006; 7: 127 31.
50. Fraser CG, Mathew CM, Mowat NAG, Wilson JA, Carey FA, Steele RJ,. Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier reflex approach. Gut 2007; 56: 1415 8.
51. Pignone M, Campbell MK, Carr C, Phillips C,. Meta-analysis of dietary restriction during fecal occult blood testing. Effect Clin Pract 2001; 4: 150 56.
52. Konrad G,. Dietary interventions for fecal occult blood test screening: systematic review of the literature. Can Fam Physician 2010; 56: 229 38.
53. Sinatra MA, St John DJ, Young GP,. Interference of plant peroxidase with guaiac-based fecal occult blood tests is avoidable. Clin Chem 1999; 45: 123 6.
54. Jaffe RM, Kasten B, Young DS, MacLowry JD,. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Int Med 1975; 83: 824 6.
55. Kahi CJ,., Imperiale TF,. Do aspirin and non-steroidal anti-inflammatory drugs cause false-positive fecal occult blood test results: a prospective study in a cohort of veterans. Am J Med 2004; 117: 837 41.
56. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Lieberman N, Klang S, Niv Y,. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009; 104: 933 8.
57. Sawhney MS, McDougall H, Nelson DB, Bond JH,. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010; 55: 1637 42.
58. Allard J, Cosby R, Del Giudice ME, Irvine EJ, Morgan D, Tinmouth J,. Gastroscopy following a positive fecal occult blood test and negative colonoscopy: systematic review and guideline. Can J Gastroenterol 2010; 24: 113 20.
59. Whitlock EP, Lin JS, Liles E, Bell TL, Fu R,. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. preventive services task force. Ann Int Med 2008; 149: 638 58.
60. van Rossum LG, van Rijn AF, Laheij RJ, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E,. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82 90.
61. Hol L, Van Leerdam ME, Van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, van der Togt AC, Habbema JD, Kuipers EJ,. Screening for colorectal cancer; randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62 8.
62. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, Tichet J, Launoy G,. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56: 210 4.
63. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, Launoy G,. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009; 100: 1230 5.
64. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J,. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 2008; 44: 2254 8.
65. Castiglione G, Sala P, Ciatto S, Grazzini G, Mazzotta A, Rossetti C, Spinelli P, Bertario L,. Comparative analysis of results of guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening in two oncological institutions. Eur J Cancer Prev 1994; 3: 399 405.
66. Smith A, Young G, Cole S, Bampton P,. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006; 107: 2152 9.
67. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y,. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther 2006; 23: 1359 64.
68. Wong BC, Wong WM, Cheung KL, Tong TS, Rozen P, Young GP, Chu KW, Ho J, Law WL, Tung HM, Lai KC, Hu WH, et al. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther 2003; 18: 941 6.
69. Oort FA, Droste JS, Van Der Hulst RW, Van Heukelem HA, Loffeld RJ, Wesdorp IC, Van Wanrooij RL, De Baaij L, Mutsaers ER, van der Reijt S, Coupe VM, Berkhof J, et al. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment Pharmacol Ther 2010; 31: 432 9.
70. Federici A, Giorgi Rossi P, Borgia P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G,. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen 2005; 12: 83 8.
71. Berchi C, Bouvier V, Réaud JM, Launoy G,. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ 2004; 13: 227 38.
72. Berchi C, Guittet L, Bouvier V, Launoy G,. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Int J Technol Assess Health Care 2010; 26: 48 53.
73. Grazzini G, Ciatto S, Cislaghi C, Castiglione G, Falcone M, Mantellini P, Zappa M,; Working Group of Regional Reference Centre for Oncological Screening of Tuscany. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence. J Med Screen 2008; 15: 175 81.
74. van Rossum LG, van Rijn AF, Verbeek AL, van Oijen MG, Laheij RJ, Fockens P, Jansen JB, Adang EM, Dekker E,. Colorectal cancer screening comparing no screening, immunochemical and guaiac faecal occult blood tests: a cost-effectiveness analysis. Int J Cancer 2010
75. Imperiale T, Ransohoff D, Itzkowitz SH, Turnbull BA, Ross ME,; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average risk population. N Engl J Med 2004; 351: 2704 14.
76. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Int Med 2008; 149: 441 450.
77. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, Kinzler KW, Vogelstein B,. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008; 135: 489 98.
78. Li M, Chen W-D, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, Levin B, Juhl H, Arber N, Moinova H, Durkee K, Schmidt K, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nature Biotechnol 2009; 27: 858 63
79. Marshall KW, Mohr S, El Khettabi F, Nossova N, Chao S, Bao W, Ma J, Li XJ, Liew CC,. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer 2010; 126: 1177 86.
80. Chan CC, Kuo YB, Fan CW, Chen YH, Chang PY, Chen KT, Hung PR, Chan EC,. Multiple serological biomarkers for colorectal cancer detection. Int J Cancer 2010; 126: 1683 90.